C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis

Autores
Aguirre, Florencia; Manin, Analisa; Fernandez, Victoria C.; Justo, Mariano Ezequiel; Leoni, Juliana; Paz, Mariela Laura; Villa, Andres Maria
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods: Levels of C3, C4, C5a, and AChR-ab were measured in 60 AChR-ab-positive patients with MG. Their relationship with clinical severity was analyzed using the activities of daily living (ADL) and MG composite (MGC) scales. Results: AChR-ab titer correlated with severity of MG according to ADL (p = 0.002) and MGC scales (p = 0.001). When patients were classified according to disease duration, a statistically significant correlation between AChR-ab titer and clinical severity was only found in the subgroup of patients with fewer than 5 years from symptoms onset. C5a levels showed a positive correlation with MG severity according to the ADL scale (p = 0.041; τb = 0.18), although C5a levels were not different from the control group. Discussion: AChR-ab titers and C5a levels could potentially be considered markers of severity in patients with MG.
Fil: Aguirre, Florencia. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Manin, Analisa. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Fernandez, Victoria C.. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Justo, Mariano Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Leoni, Juliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Paz, Mariela Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Villa, Andres Maria. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Materia
ANTI-ACETYLCHOLINE RECEPTOR ANTIBODIES
BIOMARKERS
CLINICAL SEVERITY
COMPLEMENT
MYASTHENIA GRAVIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/131812
Acceder
id CONICETDig_35893cc1b24bafafbbd63c8d4a49afc1
oai_identifier_str oai:ri.conicet.gov.ar:11336/131812
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravisAguirre, FlorenciaManin, AnalisaFernandez, Victoria C.Justo, Mariano EzequielLeoni, JulianaPaz, Mariela LauraVilla, Andres MariaANTI-ACETYLCHOLINE RECEPTOR ANTIBODIESBIOMARKERSCLINICAL SEVERITYCOMPLEMENTMYASTHENIA GRAVIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background: Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods: Levels of C3, C4, C5a, and AChR-ab were measured in 60 AChR-ab-positive patients with MG. Their relationship with clinical severity was analyzed using the activities of daily living (ADL) and MG composite (MGC) scales. Results: AChR-ab titer correlated with severity of MG according to ADL (p = 0.002) and MGC scales (p = 0.001). When patients were classified according to disease duration, a statistically significant correlation between AChR-ab titer and clinical severity was only found in the subgroup of patients with fewer than 5 years from symptoms onset. C5a levels showed a positive correlation with MG severity according to the ADL scale (p = 0.041; τb = 0.18), although C5a levels were not different from the control group. Discussion: AChR-ab titers and C5a levels could potentially be considered markers of severity in patients with MG.Fil: Aguirre, Florencia. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Manin, Analisa. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Fernandez, Victoria C.. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Justo, Mariano Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Leoni, Juliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Paz, Mariela Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Villa, Andres Maria. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaSAGE Publications2020-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/131812Aguirre, Florencia; Manin, Analisa; Fernandez, Victoria C.; Justo, Mariano Ezequiel; Leoni, Juliana; et al.; C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis; SAGE Publications; Therapeutic Advances in Neurological Disorders; 13; 8-2020; 1-81756-28641756-2864CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1177/1756286420935697info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/1756286420935697info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:58:24Zoai:ri.conicet.gov.ar:11336/131812instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:58:24.849CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
title C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
spellingShingle C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
Aguirre, Florencia
ANTI-ACETYLCHOLINE RECEPTOR ANTIBODIES
BIOMARKERS
CLINICAL SEVERITY
COMPLEMENT
MYASTHENIA GRAVIS
title_short C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
title_full C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
title_fullStr C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
title_full_unstemmed C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
title_sort C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis
dc.creator.none.fl_str_mv Aguirre, Florencia
Manin, Analisa
Fernandez, Victoria C.
Justo, Mariano Ezequiel
Leoni, Juliana
Paz, Mariela Laura
Villa, Andres Maria
author Aguirre, Florencia
author_facet Aguirre, Florencia
Manin, Analisa
Fernandez, Victoria C.
Justo, Mariano Ezequiel
Leoni, Juliana
Paz, Mariela Laura
Villa, Andres Maria
author_role author
author2 Manin, Analisa
Fernandez, Victoria C.
Justo, Mariano Ezequiel
Leoni, Juliana
Paz, Mariela Laura
Villa, Andres Maria
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTI-ACETYLCHOLINE RECEPTOR ANTIBODIES
BIOMARKERS
CLINICAL SEVERITY
COMPLEMENT
MYASTHENIA GRAVIS
topic ANTI-ACETYLCHOLINE RECEPTOR ANTIBODIES
BIOMARKERS
CLINICAL SEVERITY
COMPLEMENT
MYASTHENIA GRAVIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods: Levels of C3, C4, C5a, and AChR-ab were measured in 60 AChR-ab-positive patients with MG. Their relationship with clinical severity was analyzed using the activities of daily living (ADL) and MG composite (MGC) scales. Results: AChR-ab titer correlated with severity of MG according to ADL (p = 0.002) and MGC scales (p = 0.001). When patients were classified according to disease duration, a statistically significant correlation between AChR-ab titer and clinical severity was only found in the subgroup of patients with fewer than 5 years from symptoms onset. C5a levels showed a positive correlation with MG severity according to the ADL scale (p = 0.041; τb = 0.18), although C5a levels were not different from the control group. Discussion: AChR-ab titers and C5a levels could potentially be considered markers of severity in patients with MG.
Fil: Aguirre, Florencia. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Manin, Analisa. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Fernandez, Victoria C.. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Justo, Mariano Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Leoni, Juliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Paz, Mariela Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Villa, Andres Maria. Universidad de Buenos Aires; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
description Background: Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods: Levels of C3, C4, C5a, and AChR-ab were measured in 60 AChR-ab-positive patients with MG. Their relationship with clinical severity was analyzed using the activities of daily living (ADL) and MG composite (MGC) scales. Results: AChR-ab titer correlated with severity of MG according to ADL (p = 0.002) and MGC scales (p = 0.001). When patients were classified according to disease duration, a statistically significant correlation between AChR-ab titer and clinical severity was only found in the subgroup of patients with fewer than 5 years from symptoms onset. C5a levels showed a positive correlation with MG severity according to the ADL scale (p = 0.041; τb = 0.18), although C5a levels were not different from the control group. Discussion: AChR-ab titers and C5a levels could potentially be considered markers of severity in patients with MG.
publishDate 2020
dc.date.none.fl_str_mv 2020-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/131812
Aguirre, Florencia; Manin, Analisa; Fernandez, Victoria C.; Justo, Mariano Ezequiel; Leoni, Juliana; et al.; C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis; SAGE Publications; Therapeutic Advances in Neurological Disorders; 13; 8-2020; 1-8
1756-2864
1756-2864
CONICET Digital
CONICET
url http://hdl.handle.net/11336/131812
identifier_str_mv Aguirre, Florencia; Manin, Analisa; Fernandez, Victoria C.; Justo, Mariano Ezequiel; Leoni, Juliana; et al.; C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis; SAGE Publications; Therapeutic Advances in Neurological Disorders; 13; 8-2020; 1-8
1756-2864
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1177/1756286420935697
info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/1756286420935697
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613741106167808
score 13.070432

Publicaciones similares